ANDA 216057, held by Laurus Labs Ltd. Sitagliptin.
As of Nov 15, 2026, ANDA 216057 (Sitagliptin), held by Laurus Labs Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2025 | Original application | Tentative approval | None posted |
| Sitagliptin25MG · tablet | Sitagliptin | None (tentative approval) |
| Sitagliptin50MG · tablet | Sitagliptin | None (tentative approval) |
| Sitagliptin100MG · tablet | Sitagliptin | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters